

Infectious Diseases

## A study of long-term effects of fenebrutinib treatment in patients with chronic spontaneous urticaria

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

<b>Trial Status</b> Terminated	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> NCT03693625 2018-002296-17 GS40868
-----------------------------------	-------------------------------------	--

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a Phase II, multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with Chronic Spontaneous Urticaria (CSU) who have completed the treatment period in a fenebrutinib CSU parent study. Participants may enroll in this OLE study at any time after completing the treatment period of the parent study. Participants will receive open-label fenebrutinib at a dose of 200 milligram (mg) orally twice a day. Treatment may continue until the end of the study.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT03693625 2018-002296-17 GS40868**  
Trial Identifiers

---

### *Eligibility Criteria:*

<b>Gender</b> All	<b>Age</b> >= 18 Years & <= 75 Years	<b>Healthy Volunteers</b> No
----------------------	---	---------------------------------

---

This clinical trial was done to study a new medicine called, “fenebrutinib”, for the treatment of patients with “chronic spontaneous urticaria” or “CSU”. This study was done to find out if the long-term use of fenebrutinib was safe for patients with CSU. Researchers also wanted to find out whether fenebrutinib could provide improvements to CSU symptoms in patients when used long-term. Thirty-one patients took part in this study at nine study centers in the USA.